Preclinical Data on the Gardnerella-Specific Endolysin PM-477 Indicate Its Potential to Improve the Treatment of Bacterial Vaginosis through Enhanced Biofilm Removal and Avoidance of Resistance
Time: 1:30 pm
day: Day Two
Details:
- Bacterial vaginosis is the most frequent vaginal infection; standard of care antibiotics suffer from antimicrobial resistance formation and weak biofilm activity
- The phage-derived, engineered endolysin PM-477 is not prone to resistance formation and highly active on biofilms in vitro and on human material ex vivo
- PM-477 is being developed as an intravaginal tablet for the treatment of bacterial vaginosis
